David Yee, MD
Urology · Roseville, CANPI 1639225675
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,563 of the $202,400 with a category attached, or 79.8%. Johnson & Johnson accounts for 61.5% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $74,095, 2.4 times the $30,660 reported in 2019. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $674.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$124K
- Pfizer$30K
- Bayer$16K
- Astellas Pharma US Inc$9K
- Sumitomo Pharma America, Inc.$8K
- C. R. Bard, Inc. & Subsidiaries$7K
- plus $9K from 18 others
Across 48 payments — averaging $4666.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$190K
- Pfizer$17K
- Exact Sciences$17K
What the payments were for
- Consulting fees$8,0854%
- Speaking & faculty fees$161,56380%
- Travel & lodging$19,82810%
- Food & beverage$12,8226%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 139 | $124,460 |
| Pfizer | 45 | $30,093 |
| Bayer | 23 | $15,538 |
| Astellas Pharma US Inc | 12 | $8,586 |
| Sumitomo Pharma America, Inc. | 3 | $8,126 |
| C. R. Bard, Inc. & Subsidiaries | 23 | $6,961 |
| Janssen Scientific Affairs, LLC | 6 | $2,778 |
| Boston Scientific | 15 | $2,487 |
| Myovant Sciences Inc. | 7 | $1,249 |
| Cook Medical LLC | 3 | $314 |
| Ferring Pharmaceuticals Inc. | 4 | $279 |
| Astellas Pharma Global Development | 2 | $243 |
| AstraZeneca | 2 | $225 |
| Immunitybio, Inc. | 3 | $207 |
| Urogen Pharma, Inc. | 3 | $149 |
| Photocure Inc | 1 | $148 |
| Sanofi | 1 | $125 |
| GSK | 1 | $121 |
| KARL Storz Endoscopy-america | 1 | $98 |
| Tolmar, Inc. | 1 | $80 |
| Procept Biorobotics Corporation | 2 | $53 |
| Novartis | 1 | $44 |
| AbbVie | 1 | $18 |
| Stryker | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$73,577
- RYBREVANT$50,461
- CARVYKTI$50,461
- ORGOVYX$24,259
- XTANDI$22,581
- Nubeqa$14,332
- AKEEGA$10,132
- Bard Urinary Drainage Bag$1,030
- GENERAL KIDNEY STONE DISEASE$881
- Xofigo$872
- GENERAL BPH$650
- LithoVue$387
- Bard InLay Optima Ureteral Stent with HydroGlide Guidewire$183
- Totalis Flexible Endo Kit$161
- Lumenis Pulse 120H$161
- ANKTIVA$150
- Cysview$148
- JEVTANA$125
- FIBER DUST$122
- LYNPARZA$122
How this compares
$202,400 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 64 | $1,104,435 |
| XtandiEnzalutamide | 57 | $670,680 |
| MyrbetriqMirabegron | 148 | $117,861 |
| OrgovyxRelugolix | 36 | $94,821 |
| GemtesaVibegron | 113 | $87,756 |
| Tamsulosin Hcl | 957 | $17,208 |
| Potassium Citrate ErPotassium Citrate | 98 | $15,447 |
| Finasteride | 822 | $14,103 |
| Mirabegron ErMirabegron | 13 | $7,115 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 210 | $5,184 |
| Testosterone | 50 | $5,041 |
| Oxybutynin Chloride ErOxybutynin Chloride | 148 | $4,631 |
| Trospium Chloride | 59 | $3,996 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 94 | $1,488 |
| Tadalafil | 21 | $1,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $124,460 | $1,104,43564 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $8,586 | $788,541205 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $8,126 | $182,577149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Roseville
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.